Malecare Issued Patent For A Device and Method Which Can Reduce Secondary Tumors from Radiation Therapy

On October 27, 2015, Malecare was issued patent 9,168,002 for a device and method for real time simultaneous measurement of radiation at specific parts of your body,. Understanding cumulative radiation exposure in people undergoing ionizing radiation for diagnostics and medical treatment is essential towards reducing secondary tumors from primary radiation therapy.   We believe that the [...]

ADT with Radiation Treatment Might Endanger Your Life!

The standard of care and the facts are simple. Men who have aggressive prostate cancer and elect to have radiation therapy will benefit from six months of concurrent hormone therapy (ADT). However, based on recent findings by D’Amico etal, there seems to be a segment of men who will not benefit, but will have inferior [...]

By |2020-02-04T10:13:01-05:00September 23rd, 2015|